PT Kalbe Farma Tbk (PTKFY) AI Stock Analysis

• Market Cap: $3.43B
• Dividend Yield: 3.46%
• Average Volume (3M): 154.00
• Price to Earnings (P/E): 15.6
• Beta (1Y): 0.41
• Revenue Growth: 3.32%
• EPS Growth: 11.04%
• Country: US
• Employees: 12,841
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 0.18
• Shares Outstanding: 234,066,960
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 154
• PEG Ratio: 1.37
• Price to Book (P/B): 3.38
• Price to Sales (P/S): 2.36
• P/FCF Ratio: 21.81
• Enterprise Value/Market Cap: 1.22
• Enterprise Value/Revenue: <0.01
• Enterprise Value/Gross Profit: <0.01
• Enterprise Value/Ebitda: <0.01
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 72 Outperform
• Price Target: $18.00 ▲(29.12% Upside)

PT Kalbe Farma Tbk's strong financial performance is the most significant factor, with robust revenue growth and profitability supporting a solid score. The technical analysis indicates some bearish momentum, which slightly offsets the financial strengths. The valuation is moderate, with a reasonable P/E ratio and attractive dividend yield, contributing positively to the overall score.

Positive Factors

Revenue Growth

The company has shown impressive revenue growth of 81.2% in the TTM period, indicating robust business expansion and strong market demand for its products.

Balance Sheet Health

Low leverage and financial risk enhance the company's financial stability, providing a solid foundation for future growth and resilience against economic fluctuations.

Profitability

Strong profit margins reflect efficient cost management and pricing power, supporting sustainable profitability and competitive advantage in the market.

Negative Factors

Free Cash Flow Growth

Negative free cash flow growth could hinder the company's ability to invest in new opportunities and maintain operational flexibility, posing a risk to long-term growth.

Stockholders' Equity

A decrease in stockholders' equity may indicate challenges in retaining earnings or potential dilution, impacting shareholder value and financial health over time.

Cash Flow Metrics

Weakness in cash flow metrics suggests potential issues in cash generation, which could affect the company's ability to fund operations and growth initiatives sustainably.

PT Kalbe Farma Tbk Business Overview & Revenue Model

Company Description

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. It offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG that are distributed to hospitals, pharmacies, and drug stores. The company also provides over-the-counter drugs; energy drinks, ready-to-drink products, supplements, and other preventive products; and nutritional products for infants, toddlers, children, teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs. In addition, it offers contract services, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products, as well as operates Mitrasana Clinics, a health care service. Further, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia.

How the Company Makes Money

PT Kalbe Farma generates revenue through multiple key streams, including the sale of prescription pharmaceuticals, over-the-counter medications, and nutritional products. The company's prescription drug segment is particularly important, contributing significantly to its overall sales, as it caters to healthcare providers and hospitals. Additionally, Kalbe has a robust nutritional and consumer health division that leverages the growing demand for health supplements and wellness products. The company also benefits from strategic partnerships and collaborations with other healthcare organizations, enhancing its research capabilities and expanding its product offerings. Factors such as an increasing population, rising healthcare awareness, and the expansion of healthcare infrastructure in Indonesia contribute to the growth of Kalbe Farma's earnings.

PT Kalbe Farma Tbk Financial Statement Overview

Summary

PT Kalbe Farma Tbk demonstrates strong financial health with robust revenue growth and profitability. The company maintains a solid balance sheet with low leverage, enhancing financial stability. While cash flow metrics show some areas for improvement, particularly in Free Cash Flow Growth, the overall financial position remains strong, supporting continued growth and operational efficiency.

Income Statement

PT Kalbe Farma Tbk exhibits strong income statement metrics with a consistent increase in revenue and profitability. The TTM Gross Profit Margin is healthy at 40.18%, and the Net Profit Margin is solid at 10.22%. The company has shown impressive revenue growth of 81.2% in the TTM period, indicating robust business expansion. EBIT and EBITDA margins are also strong, reflecting efficient operational management.

Balance Sheet

The balance sheet of PT Kalbe Farma Tbk is stable with a low Debt-to-Equity Ratio of 0.0348, indicating low leverage and financial risk. The Return on Equity (ROE) is commendable at 15.01%, showcasing effective use of equity capital. The Equity Ratio is strong, suggesting a solid capital structure. However, the slight decrease in Stockholders' Equity over the periods could be a point to monitor.

Cash Flow

Cash flow analysis reveals a mixed picture. The Free Cash Flow Growth Rate is negative at -20.9% in the TTM, which could be a concern. However, the Operating Cash Flow to Net Income Ratio is healthy at 0.799, indicating good cash generation relative to net income. The Free Cash Flow to Net Income Ratio is also strong at 0.787, reflecting efficient cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	33.38T	32.63T	30.45T	28.93T	26.26T	23.11T
Gross Profit	13.52T	12.96T	11.82T	11.70T	11.28T	10.25T
EBITDA	4.87T	4.61T	4.02T	5.25T	4.87T	4.35T
Net Income	3.41T	3.24T	2.77T	3.38T	3.18T	2.73T
Balance Sheet
Total Assets	29.51T	29.43T	27.06T	27.24T	25.67T	22.56T
Cash, Cash Equivalents and Short-Term Investments	3.95T	4.87T	3.40T	4.10T	6.48T	5.40T
Total Debt	779.98B	559.22B	618.54B	1.17T	626.16B	1.16T
Total Liabilities	5.32T	4.84T	3.94T	5.14T	4.40T	4.29T
Stockholders Equity	22.40T	22.79T	21.42T	20.39T	19.58T	17.41T
Cash Flow
Free Cash Flow	2.87T	3.53T	1.73T	2.90T	1.83T	3.10T
Operating Cash Flow	3.71T	4.79T	2.91T	3.77T	2.83T	4.21T
Investing Cash Flow	-439.87B	-1.25T	-1.14T	-1.37T	-1.06T	-951.22B
Financing Cash Flow	-3.15T	-2.09T	-2.44T	-2.41T	-745.18B	-1.10T

PT Kalbe Farma Tbk Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 13.94
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PTKFY, the sentiment is Negative. The current price of 13.94 is below the 20-day moving average (MA) of 14.62, below the 50-day MA of 14.33, and below the 200-day MA of 15.67, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 44.12 is Neutral, neither overbought nor oversold. The STOCH value of 30.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PTKFY.

PT Kalbe Farma Tbk Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GRFS	72 Outperform	$7.58B	14.41	6.93%	1.61%	9.45%	167.00%
PTKFY	72 Outperform	$3.43B	15.60	15.61%	3.46%	3.32%	11.04%
OGN	54 Neutral	$1.86B	3.71	71.62%	4.76%	-1.69%	-61.89%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SRXH	48 Neutral	$9.98M	0.16	―	―	-8.12%	―
CTOR	47 Neutral	$131.12M	―	―	―	―	―